Dapagliflozin Reduces Diabetes and Heart Failure Risk Post-MI, Especially in Prediabetic and Obese Patients: Study

Day 1 conference highlights include news from Moderna, BridgeBio

DRRA21 hours ago 0

FDA again rejects tabelecleucel for EBV-driven post-transplant lymphoproliferative disease

DRRA21 hours ago 0

New data, nuances in managing resistant gram-negative infections

DRRA22 hours ago 0

New Year’s resolutions 2026: Lessons from colleagues

DRRA22 hours ago 0